Open AccessImmunological evaluation of personalized peptide vaccination in combination with a 5‐fluorouracil derivative (TS‐1) for advanced gastric or colorectal carcinoma patients
Author(s) -
Sato Yuji,
Fujiwara Toshiyoshi,
Mine Takashi,
Shomura Hiroki,
Homma Shigenori,
Maeda Yoshiaki,
Tokunaga Naoyuki,
Ikeda Yoshihiro,
Ishihara Yuki,
Yamada Akira,
Tanaka Noriaki,
Itoh Kyogo,
Harada Mamoru,
Todo Satoru
Publication year - 2007
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2007.00498.x
Subject(s) - fluorouracil , medicine , vaccination , gastric carcinoma , peptide , colorectal cancer , derivative (finance) , oncology , cancer research , gastroenterology , immunology , chemotherapy , cancer , biology , biochemistry , economics , financial economics
The aim of the present study was to investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of a 5‐fluorouracil derivative (TS‐1) in advanced gastric or colorectal carcinoma patients. Eleven patients (four with gastric cancer and seven with colorectal cancer) who failed to improve by prior TS‐1‐based chemotherapies were enrolled in this study. Peptides to be administered to patients were determined based on the presence of peptide‐specific cytotoxic T lymphocyte (CTL) precursors in peripheral blood mononuclear cells and peptide‐specific IgG in the plasma of cancer patients. Patients were vaccinated with peptides (a maximum of four) biweekly in combination with or without three different doses of TS‐1 (20, 40 and 80 mg/m 2 /day). Although grade 3 toxicity, including anemia (one patient) and neutropenia (one patient) were observed, the combination therapy was generally well tolerated. An increase in peptide‐specific IgG after the sixth vaccination was observed in the vast majority of patients irrespective of the dose of TS‐1 used. In contrast, an increase in peptide‐specific interferon‐γ production by CTL was most evident in patients who were administered the highest dose of TS‐1. Furthermore, in the patients who received 80 mg/m 2 /day TS‐1, CTL‐mediated cytotoxicity against cancer cells was maintained at the prevaccination level. These results indicate that administration of the standard dose (80 mg/m 2 /day) of TS‐1 in combination with a personalized peptide vaccination does not necessarily impede immunological responses in cancer patients, and could actually maintain or augment them. ( Cancer Sci 2007; 98: 1113–1119)